Mylan Settles With Orion Over Planned Stalevo Generic

Law360, New York (July 25, 2013, 2:38 PM EDT) -- Mylan Inc. on Thursday announced it had reached a settlement with Orion Corp. over its planned generic version of Parkinson's disease treatment Stalevo, ending a patent infringement dispute in Delaware federal court.

As part of the settlement, Canonsburg, Pa.-based Mylan has signed a licensing agreement with Orion, allowing it to launch an authorized generic carbidopa, levodopa and entacapone combination treatment in six different dosage strengths immediately after court approval of the deal, the companies said.

Mylan will also be allowed to launch its own generic version...
To view the full article, register now.